[HTML][HTML] The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
…, K Geisinger, FR Hirsch, Y Ishikawa, KM Kerr… - Journal of thoracic …, 2015 - Elsevier
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura,
Thymus and Heart has just been published with numerous important changes from the 2004 …
Thymus and Heart has just been published with numerous important changes from the 2004 …
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
…, S Bhalla, MB Beasley, LM Sholl, KM Kerr… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
Chronic thromboembolic pulmonary hypertension
PF Fedullo, WR Auger, KM Kerr… - New England Journal of …, 2001 - Mass Medical Soc
Chronic Thromboembolic Pulmonary Hypertension | NEJM Skip to main content NEJM Group
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician …
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician …
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr… - Annals of …, 2017 - annalsofoncology.org
Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …
[HTML][HTML] PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project
…, J Walker, J Longshore, MS Tsao, KM Kerr - Journal of Thoracic …, 2017 - Elsevier
Introduction The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC)
Assay Comparison Project is an industrial-academic collaborative partnership to provide …
Assay Comparison Project is an industrial-academic collaborative partnership to provide …
Pulmonary endarterectomy: experience and lessons learned in 1,500 cases
…, GR Manecke, PA Thistlethwaite, KM Kerr… - The Annals of thoracic …, 2003 - Elsevier
BACKGROUND: The incidence of pulmonary hypertension resulting from chronic thrombotic
occlusion of the pulmonary arteries is significantly underestimated. Although medical …
occlusion of the pulmonary arteries is significantly underestimated. Although medical …
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
…, N Reinmuth, D De Ruysscher, KM Kerr… - Annals of …, 2014 - annalsofoncology.org
Primary lung cancer is the most common malignancy after nonmelanocytic skin cancer with
deaths from lung cancer exceeding those from any other type of malignancy worldwide [1]. …
deaths from lung cancer exceeding those from any other type of malignancy worldwide [1]. …
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1, …
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1, …
Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial
MH Kollef, B Afessa, A Anzueto, C Veremakis, KM Kerr… - Jama, 2008 - jamanetwork.com
Context Ventilator-associated pneumonia (VAP) causes substantial morbidity. A silver-coated
endotracheal tube has been designed to reduce VAP incidence by preventing bacterial …
endotracheal tube has been designed to reduce VAP incidence by preventing bacterial …